Barinthus Biotherapeutics (BRNS) Q2 Virtual Investor Summit Event earnings summary

Strategic focus and platform overview

• Focused on next-generation immunotherapies for autoimmune and inflammatory diseases, leveraging the SNAP-TI self-assembling nanoparticle platform.

• SNAP-TI enables antigen-specific immune tolerance, aiming for more effective and patient-friendly treatments.

• Lead candidate VTP-1000 targets celiac disease, currently in phase I clinical trials with data expected late Q3 or early Q4.

• Additional preclinical candidates are in development, with a strong cash position of $100 million and no debt.

• Viral-based infectious disease and oncology programs are being wound down, with partnering opportunities sought.

Scientific and clinical program updates

• SNAP-TI platform co-delivers multiple disease-associated antigens and an immunomodulator, aiming to rebalance Treg and T effector cells.

• Preclinical data show improved tolerability, broad antigen coverage, and effective immune modulation in models of multiple sclerosis.

• VTP-1000 uses rapamycin as an immunomodulator to dampen pro-inflammatory responses and promote Treg skewing.

• Phase I trial is double-blind, placebo-controlled, with single and multiple ascending dose cohorts; FDA approval received for MAD portion.

• SAD data expected late Q3/early Q4; MAD data anticipated mid-next year.

Market opportunity and disease focus

• Celiac disease affects about 1% of the global population, with significant unmet need due to limitations of gluten-free diets.

• VTP-1000 aims to restore immune balance by reducing T effector cells and stimulating Tregs, potentially offering a novel therapy.

• Manufacturing process allows for consistent, scalable production and patient-friendly administration (IM or subcutaneous).

• Additional indications explored include multiple sclerosis, vitiligo, and type 1 diabetes, with further clinical guidance expected next year.